☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
novartis
The US FDA Approves Novartis’ Scemblix for Newly Diagnosed Ph+ CML in Chronic Phase
October 30, 2024
Monte Rosa Therapeutics and Novartis Collaborate to Advance VAV1-directed Molecular Glue Degraders (MGD)
October 29, 2024
Novartis Reports Data from P-III (APPEAR-C3G) Study of Fabhalta (Iptacopan) in C3 Glomerulopathy (C3G)
October 28, 2024
Novartis’ Kisqali (Ribociclib) Gains the CHMP’s Positive Opinion as an Adjuvant Treatment of HR+/HER2- Early Breast Cancer (EBC)
October 18, 2024
PharmaShots Weekly Snapshots (September 16 – September 20, 2024)
September 20, 2024
Novartis Reports the US FDA’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer
September 18, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.